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Low-Density Lipoprotein
Cholesterol?
The U.S. National Cholesterol Education Program Expert Panel
on Detection, Evaluation, and Treatment of High Blood Choles-
terol in Adults recommendations (1) have had a huge impact on
the treatment of hypercholesterolemia around the world and have
had a decisive inﬂuence on all recommendations worldwide. Until
now, the recommendations were based on lowering low-density
lipoprotein cholesterol (LDL-C) as the treatment goal. The
accumulated information for more than 100 years built the “lipid
theory of atherosclerosis” (2), and the recommendations ﬁt well
with that scientiﬁc knowledge: lowering LDL-C reduces cardio-
vascular risk by reducing atherosclerosis, and LDL-C lowering is,
therefore, the objective. Over the years, as the evidence from clinical
trials has emerged, LDL-C goal levels have been reduced and thepopulation subsidiaries of reduction beneﬁt have been expanding.
The results have been dramatic and the reduction of cardiovascular
disease in many countries reﬂects this (3).
The recently published “2013 ACC/AHA Guideline on the
Treatment of Blood Cholesterol to Reduce Atherosclerotic Car-
diovascular Risk in Adults” (4) has substantially changed the
message. What is important, according to the new guideline, is to
prescribe statins, and cholesterol reduction is a consequence, not
the goal, of treatment. The guidelines have gone from a low-density
lipoprotein–focused vision to a vision focused only on statins. They
forget lipid goals, the concentration of cholesterol in the moni-
toring of patients, and, ultimately, all evidence of the pathogenesis
of atherosclerosis. The document concentrates only on 1 type of
evidence, which comes from randomized clinical trials. It should be
remembered that not all scientiﬁc evidence comes from randomized
clinical trials, and that we will never be able to have solid evidence
for many patients excluded from the trials. What are we to do
with a diabetic patient of age 60 years, with a personal history of
coronary disease and with LDL-C 130 mg/dl after maximally-
tolerated doses of statins? The document tells us to do nothing to
further reduce his LDL-C. We believe that the scientiﬁc knowl-
edge is misinterpreted, and a large group of patients is being un-
reasonably discriminated against. In contrast, the document
indicates that we should prescribe high-intensity statin treatment in
an otherwise healthy woman of 21 years, with LDL-C 190 mg/dl
and, for example, high-density lipoprotein cholesterol 90 mg/dl.
Even the document supports the use of a second or third nonstatin
lipid-lowering drug to further lower her LDL-C; however, it re-
fuses this approach to our diabetic patient.
The document has, according to the Spanish Atherosclerosis
Society, many positive aspects: the systematic review of the
literature, the deﬁnition of the groups susceptible to treatment,
the classiﬁcation of the statins’ effects, and the new calculation of
cardiovascular risk. However, the uncertainty and nihilism in many
important issues is worrisome and may harm many patients; leaving
behind the concept of intensive reduction of LDL-C will confuse
many doctors; and focusing on statins will be detrimental to the
investigation and development of other lipid-lowering drugs. For
these reasons, the Spanish Society of Arteriosclerosis does not
support this document and better recommends the guidelines
from the European Society of Cardiology/European Atherosclerosis
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Low-Density Lipoprotein
Cholesterol?The ACCF/AHA welcomes letters to inform its ongoing work and
encourages such correspondence about its guidelines. Because the
ACCF/AHA guideline development process is rigorous and in-
volves several layers of review by the writing committee, external
peer reviewers, and participating organizations in the document, it
cannot respond to each issue raised after a guideline has been
published. The information, however, is forwarded to the writing
committee chair and oversight task force for review. If any issue is
deemed by the ACCF/AHA to affect patient safety, it will be
considered immediately. Otherwise, the information will be
considered during the next update or revision of the guideline.The American College of Cardiology
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